Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease.

IF 3.4 Q2 GASTROENTEROLOGY & HEPATOLOGY

Intestinal Research Pub Date : 2023-10-01 Epub Date: 2023-09-01 DOI:10.5217/ir.2023.00039

You Sun Kim, Edward H Hurley, Yoojeong Park, Sungjin Ko

引用次数: 0

Abstract

Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with this disease have an increased risk of malignancy development, such as colorectal cancer and cholangiocarcinoma. The pathogenesis of PSC-IBD involves genetic and environmental factors such as gut dysbiosis and bile acids alteration. However, despite the advancement of disease characteristics, no effective medical therapy has proven to have a significant impact on the prognosis of PSC. The treatment options for patients with PSC-IBD do not differ from those for patients with PSC alone. Potential candidate drugs have been developed based on the pathogenesis of PSC-IBD, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis. In this review, we summarize the current medical treatments for PSC-IBD and the status of new emerging therapeutic agents.

Abstract Image

查看原文本刊更多论文

原发性硬化性胆管炎合并炎症性肠病的治疗。

原发性硬化性胆管炎（PSC）是一种进行性胆汁淤积、炎症和纤维化疾病，与炎症性肠病（IBD）密切相关。PSC-IBD代表一种独特的疾病实体，患有这种疾病的患者发生恶性肿瘤的风险增加，如结直肠癌癌症和胆管癌。PSC-IBD的发病机制涉及遗传和环境因素，如肠道微生态失调和胆汁酸改变。然而，尽管疾病特征有所改善，但没有任何有效的药物治疗被证明对PSC的预后有显著影响。PSC-IBD患者的治疗选择与单独患有PSC的患者没有区别。基于PSC-IBD的发病机制，已经开发出潜在的候选药物，例如那些靶向胆汁酸、炎症、纤维化和肠道微生态失调的药物。在这篇综述中，我们总结了目前PSC-IBD的医学治疗方法和新兴治疗剂的现状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Intestinal Research GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.40

自引率

10.20%

发文量

审稿时长

38 weeks

期刊介绍： Intestinal Research (Intest Res) is the joint official publication of the Asian Organization for Crohn''s and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn''s Foundation (India) (CCF, india). The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include inflammatory bowel disease, colon and small intestine cancer or polyp, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth. The Journal publishes diverse types of academic materials such as editorials, clinical and basic reviews, original articles, case reports, letters to the editor, brief communications, perspective, statement or commentary, and images that are useful to clinicians and researchers.